Premium
LINC00460 promotes pancreatic cancer progression by sponging miR‐491‐5p
Author(s) -
Wu Jiali,
Sun Shuxin,
Liao Wei,
Chen Enni,
Wang Xiaonan,
Song Yunda,
Duan Fangting,
Deng Wuguo,
Li Shengping
Publication year - 2021
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.3333
Subject(s) - gene knockdown , cancer research , cell growth , carcinogenesis , cell cycle , flow cytometry , biology , downregulation and upregulation , pancreatic cancer , apoptosis , cell , cancer , immunology , gene , biochemistry , genetics
Abstract Background A growing body of studies have suggested that LINC00460 is instrumental in tumorigenesis and tumour progression. Nonetheless, the biological function and mechanisms of LINC00460 in pancreatic ductal adenocarcinoma (PDAC) remain vague. Methods Analysis based on public databases and a quantitative reverse transcription‐polymerase chain reaction were performed to screen for differentially expressed lncRNAs in PDAC and to detect LINC00460 expression in PDAC cell lines and clinical samples. The survival of patients in the up‐regulated and down‐regulated LINC00460 expression groups was compared by using the Kaplan–Meier method. In addition, the potential biological functions of LINC00460 in PDAC were explored by cell counting kit‐8, colony formation, flow cytometry and transwell assays. Furthermore, bioinformatics analysis, luciferase reporter assays and rescue experiments were applied to demonstrate the mechanism by which LINC00460 could directly bind to and inhibit miR‐491‐5p. Results LINC00460 is up‐regulated in PDAC and correlates with adverse survival outcomes. The results of functional tests verified that LINC00460 knockdown inhibited both cell proliferation and cell migration. Additionally, knockdown led to G0/G1 cell cycle blockage and enhanced cell apoptosis. Mechanistic investigations revealed that LINC00460 directly binds to and attenuates the tumour suppressor miR‐491‐5p, thus accelerating PDAC progression. Conclusions This research showed that LINC00460 is overexpressed in PDAC and correlates with adverse clinical outcomes. Additionally, LINC00460 promotes the aggressiveness of PDAC by targeting miR‐491‐5p. Thus, LINC00460 may serve as diagnostic biomarker of PDAC and a new target for PDAC therapy.